AN2 Therapeutics Posts Trial Data for Chagas Disease Therapy

AN2 Therapeutics (ANTX) rose approximately 7% in premarket trading after releasing results from two early-stage trials of its experimental therapy, AN2-502998, for treating Chagas disease. The biopharmaceutical company reported positive data that could support further development.

By Dulan Lokuwithana, SA News Editor · Seeking Alpha · June 4, 2026, 12:21 UTC

AN2 Therapeutics Posts Trial Data for Chagas Disease Therapy

Topics: AN2-502998 Chagas disease premarket stock movement

Read the full article at Seeking Alpha

More World news

CEZ Reports 9M Revenue Growth and 24% Increase in Net Income Seeking Alpha · November 12, 2026, 15:05 UTC
BlueMatrix Completes Acquisition of AI-Enabled Research Platform Aiera PR Newswire · November 12, 2026, 15:15 UTC
U.S. Lawmakers Respond to Jensen Huang's Resignation as Nvidia CEO Seeking Alpha · November 12, 2026, 15:12 UTC
OpenAI Secures $15 Billion in New Funding at $1.25 Trillion Valuation Seeking Alpha · November 12, 2026, 15:13 UTC
Digi International Shares Fall 18% Following Fiscal Q4 Earnings Release Seeking Alpha · November 12, 2026, 15:13 UTC
Pomerantz Law Firm Investigates Artiva Biotherapeutics Following Program Discontinuation and Fatal Safety Events PR Newswire · November 12, 2026, 15:15 UTC
Major Corporate Earnings Scheduled for Release After Thursday Market Close Seeking Alpha · November 12, 2026, 15:00 UTC
U.S. Existing Home Sales Decline More Than Expected in October Seeking Alpha · November 12, 2026, 15:03 UTC
Ascendis Pharma Reports Strong Q3 2026 Results Driven by Yorvipath Growth Motley Fool · November 12, 2026, 15:09 UTC
Pomerantz Law Firm Investigates Omeros Corporation Following Regulatory Setbacks PR Newswire · November 12, 2026, 15:10 UTC